A versatile self-amplifying mRNA system consolidates oncolytic virus benefits into a single flexible backbone for cancer therapy
- 3 January 2026
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 34 (4) , 2134-2153
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82473319)
- National Natural Science Foundation of China (92359303)
- National Natural Science Foundation of China (82272300)
- National Key Research and Development Program of China (2024YFA1803100)
- Natural Science Foundation of Zhejiang Province (LR25H160002)
This publication has 58 references indexed in Scilit:
- Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patientsCell, 2025
- Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrenceActa Pharmaceutica Sinica B, 2023
- ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccinesCell, 2023
- Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancerMolecular Therapy Nucleic Acids, 2022
- The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potencyJournal of Controlled Release, 2021
- Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspectiveCancer Cell, 2021
- Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selectionJournal of Controlled Release, 2020
- A novel rabies vaccine based on infectious propagating particles derived from hybrid VEEV-Rabies repliconEBioMedicine, 2020
- Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particlesBiochemical and Biophysical Research Communications, 2018
- Basic and translational applications of engineered MHC class I proteinsTrends in Immunology, 2010